203 related articles for article (PubMed ID: 30246355)
1. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
[TBL] [Abstract][Full Text] [Related]
2. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
4. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
8. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
9. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
10. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
Liu B; Su F; Lv X; Zhang W; Shang X; Zhang Y; Zhang J
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1039-1049. PubMed ID: 31482230
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer.
Rigakos G; Razis E; Koliou GA; Oikonomopoulos G; Tsolaki E; Sperinde J; Chrisafi S; Zarkavelis G; Pazarli E; Batistatou A; Kourea HP; Papakostas P; Bafaloukos D; Asimakopoulou NI; Res E; Kotsakis A; Pectasides D; Koutras A; Christodoulou C; Fountzilas G
Anticancer Res; 2021 Apr; 41(4):1793-1802. PubMed ID: 33813384
[TBL] [Abstract][Full Text] [Related]
12. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
[TBL] [Abstract][Full Text] [Related]
13. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
[TBL] [Abstract][Full Text] [Related]
14. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
[TBL] [Abstract][Full Text] [Related]
15. Radiological complete remission in HER2-positive metastatic breast cancer patients: what to do with trastuzumab?
Steenbruggen TG; Bouwer NI; Smorenburg CH; Rier HN; Jager A; Beelen K; Ten Tije AJ; de Jong PC; Drooger JC; Holterhues C; Kitzen JJEM; Levin M-; Sonke GS
Breast Cancer Res Treat; 2019 Dec; 178(3):597-605. PubMed ID: 31493033
[TBL] [Abstract][Full Text] [Related]
16. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
17. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2015 Jan; 112(1):103-11. PubMed ID: 25349977
[TBL] [Abstract][Full Text] [Related]
20. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M; Dafni U; Gnant M; Polydoropoulou V; Hills M; Kiermaier A; de Azambuja E; Larsimont D; Rojo F; Viale G; Toi M; Harbeck N; Prichard KI; Gelber RD; Dinh P; Zardavas D; Leyland-Jones B; Piccart-Gebhart MJ; Dowsett M;
Clin Cancer Res; 2018 Jul; 24(13):3079-3086. PubMed ID: 29530933
[No Abstract] [Full Text] [Related]
[Next] [New Search]